ST3GAL1 as a novel biomarker of lack of sustained MRD negativity in multiple myeloma

Michael O'Dwyer, MD, PhD, National University of Ireland, Galway, Ireland, speaks about a study investigating the increased expression of the sialyltransferase gene (ST3GAL1) as a biomarker for predicting lack of sustained measurable residual disease (MRD) negativity in patients with multiple myeloma. Dr O'Dwyer highlights that high levels of ST3-GAL1 expression are associated with inferior progression-free survival and increased risk of relapse. This finding suggests that ST3-GAL1 could be a new biomarker to identify patients at higher risk of treatment failure and, potentially, a target for novel therapies that reduce excessive sialic acid. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.